UGT1A1 and colorectal cancer: Moreover, combinational analysis of DPYD and UGT1A1 genotypes in Italian colorectal cancer patients receiving fluoropyrimidines/irinotecan revealed that the incremental cost between DPYD variant and UGT1A1*28/*28 carriers and non-carriers was €2,975, indicating the relevance of these pharmacogenetic traits also from an economic perspective[40].